- J&J announced that it will stop selling talc-based baby powder abroad in 2023.
- The company is dealing with almost 38,000 claims from clients alleging that the product caused cancer.
- The company has consistently refuted the claims in response to asbestos contamination evidence given in courtrooms.
More than two years after ceasing sales of the product in the US, where it has generated hundreds of consumer safety lawsuits, Johnson & Johnson (J&J) announced on Thursday that it will stop selling talc-based baby powder abroad in 2023.
The statement clarified that cornstarch-based baby powder is already available in many nations throughout the world and said, “As part of a worldwide portfolio assessment, we have made the commercial decision to migrate to an entirely cornstarch-based baby powder portfolio.”
In the middle of numerous legal battles, J&J announced in 2020 that it will stop selling its talc Baby Powder in the United States and Canada because consumer demand had decreased as a result of what it called “misinformation” about the product’s safety.
The business is dealing with almost 38,000 claims from clients and their families alleging that the company’s talc products caused cancer due to asbestos contamination, a proven carcinogen.
According to an international news agency’s investigation from 2018, J&J had long known that asbestos was contained in its talc products.
According to the agency, J&J’s finished powders and raw talc occasionally tested positive for trace levels of asbestos from at least 1971 through the early 2000s, according to corporate documents, trial testimony, and other evidence.
The company has consistently refuted the claims in response to asbestos contamination evidence given in courtrooms, in media stories, and before US lawmakers.
J&J disputes these allegations, claiming that years of research and governmental approvals have established the safety and absence of asbestos in its talc.
On Thursday, when it announced that it would be ending its sales, it reiterated the same.
In October, J&J established the subsidiary LTL Management, transferred its talc claims to it, and then swiftly declared it bankrupt, stopping the ongoing legal proceedings.
While proponents of J&J and the bankrupt subsidiary procedure argue that it is a just means to compensate complainants, those petitioning against the firm have argued that the company should be had to defend itself against the litigation.
[embedpost slug=”johnson-johnson-ordered-to-pay-302m-in-pelvic-mesh-case/”]
